BioWorld

Sep. 30, 2005

View Archived Issues

Cypress' Stock Plunges After Phase III Miss In Fibromyalgia

Cypress Bioscience Inc. lost more than half its value Thursday after announcing that a pivotal Phase III study of milnacipran missed its primary endpoint as a treatment for pain associated with fibromyalgia. (BioWorld Today) Read More

Sirna's RNAi Work Lands $250M Deal With Allergan

Read More

New Research: Target Host Cells To Help Fight Viruses

Read More

Avalon Sets IPO Price: $28.9M Pipeline Boost

Read More

Genomic Health's IPO Adds $60M For Breast Cancer Test

Read More

Other News To Note

Read More

Appointments And Advancements

Read More

U.S. Patent Disclosures

Read More